store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PD-166793是一种具有口服活性、有效性和选择性的 MMP 抑制剂,对 MMP-2,MMP-3 和 MMP-13 具有抑制作用。PD-166793 在大鼠心力衰竭模型中改善心肌缺血和再灌注损伤。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 542 | 现货 | ||
5 mg | ¥ 913 | 现货 | ||
10 mg | ¥ 1,390 | 现货 | ||
25 mg | ¥ 2,890 | 现货 | ||
50 mg | ¥ 4,660 | 现货 | ||
100 mg | ¥ 7,450 | 现货 | ||
500 mg | ¥ 14,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 983 | 现货 |
产品描述 | PD-166793 is an orally active, potent and selective MMP inhibitor with inhibitory effects on MMP-2, MMP-3 and MMP-13.PD-166793 ameliorates myocardial ischemia and reperfusion injury in a rat model of heart failure.PD-166793 is an orally active, potent and selective MMP inhibitor with inhibitory effects on MMP-2, MMP-3, and MMP-13. |
靶点活性 | MMP9:7.9 μM, MMP1:6.0 μM, MMP13:8 nM, MMP7:7.2 μM, MMP3:7 nM, MMP2:4 nM |
体外活性 | In rat heart homogenates, PD-166793 at a concentration of 0.1 μM results in a 20% inhibition of AMP deaminase (AMPD) activity[2]. Additionally, when normal human cardiac fibroblasts are treated with PD-166793 at a concentration of 100 μM for 36 hours, there is a significant reduction in MMP‐9 activity[1]. |
体内活性 | Administered at a dosage of 1 mg/kg per day through daily gavage for a duration of 10 weeks, PD-166793 largely prevents the adverse remodeling typically observed in the aortocaval (AV) fistula model[3]. Furthermore, in rats, PD-166793 administered at a dose of 5 mg/kg via oral gavage demonstrates superior pharmacokinetics, with a half-life (t1/2) of 43.6 hours, a maximum concentration (Cmax) of 42.4 µg/mL, and an area under the curve from 0 to infinity (AUC0-∞) of 2822 µg•h/mL[2]. |
别名 | PD-166793-0000, PD 166793, PD166793 |
分子量 | 412.3 |
分子式 | C17H18BrNO4S |
CAS No. | 199850-67-4 |
store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL(194.03 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.4254 mL | 12.1271 mL | 24.2542 mL | 60.6355 mL |
5 mM | 0.4851 mL | 2.4254 mL | 4.8508 mL | 12.1271 mL | |
10 mM | 0.2425 mL | 1.2127 mL | 2.4254 mL | 6.0635 mL | |
20 mM | 0.1213 mL | 0.6064 mL | 1.2127 mL | 3.0318 mL | |
50 mM | 0.0485 mL | 0.2425 mL | 0.4851 mL | 1.2127 mL | |
100 mM | 0.0243 mL | 0.1213 mL | 0.2425 mL | 0.6064 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
PD-166793 199850-67-4 Proteases/Proteasome MMP PD-166793-0000 PD 166793 PD166793 Inhibitor inhibitor inhibit